Phase II study with docetaxel (D), cisplatin (C) and continuous capecitabine (X) schedule (DCX) in advanced gastric cancer (AGC): ML21085. Final results.

e15520Background: Activity in first line in AGC with D, C and Fluorouracil (V325 study) has been described. Two studies evaluated schedules with X (REAL-2 and ML 17032). But there is no much inform...